AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Berenberg raised AbbVie’s price target from $165 to $195 while maintaining a Hold rating. The firm increased its estimates due to stronger-than-expected immunology sales. AbbVie’s stock has surged 22% ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie has surged 9.9% in the past month, outperforming the S&P 500’s 7.4% decline. Earnings estimates suggest a solid ...

After hours: March 12 at 7:57:57 PM EDT Loading Chart for ABBV ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Forbes contributors publish independent expert analyses and insights. Building a platform to do the job of 1 million analysts ...

Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...